Home > GAMMAGARD Products > GAMMAGARD LIQUID IV > Tolerability

Tolerability
GAMMAGARD LIQUID - IV Administration

Protecting life's moments with an established tolerability profile1


 
(381/400) of non-serious adverse reactions (ARs) reported in this study were considered mild (217) or moderate (164).
(The remaining 5% [19/400] were rated severe)
 
of non-serious ARs were mild (n=217)
Mild ARs were defined as transient discomfort that resolves spontaneously or with minimal intervention
 
of non-serious ARS were moderate (n=164)
Moderate ARs were defined as limited impairment of function that resolves spontaneously or with minimal intervention with no sequelae
 
of non-serious ARs were severe (n=19)
All 19 severe ARs resolved without complications or hospitalization
Severe ARs were defined as marked impairment of function or can lead to temporary inability to resume normal life pattern; requires prolonged intervention or results in sequelae

 
  • One subject withdrew from the study due to a non-serious adverse experience (papular rash)
  • Fifteen adverse reactions in 8 subjects were serious. Of these, two episodes of aseptic meningitis in one patient were deemed possibly related to the infusion of GAMMAGARD LIQUID

Reference: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc.


  • Your patients can get access to experienced Patient and Nurse Advocates, insurance and financial support, useful tools, and more.
    Find Out How
  • Choosing IV or SC Which is the right choice for your patient? Compare the differences using our chart.
    Take a Look
  • Insurance Assistance For access to experts who can provide expedited benefits verification and other insurance coverage resources, call 1-855-250-5111.
Error processing SSI file